Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register - PubMed (original) (raw)
doi: 10.1136/ard.2007.085852. Epub 2008 May 8.
E Baecklund, F Granath, P Geborek, M Fored, C Backlin, L Bertilsson, L Cöster, L T Jacobsson, S Lindblad, J Lysholm, S Rantapää-Dahlqvist, T Saxne, R van Vollenhoven, L Klareskog, N Feltelius
Affiliations
- PMID: 18467516
- DOI: 10.1136/ard.2007.085852
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
J Askling et al. Ann Rheum Dis. 2009 May.
Abstract
Background: Tumour necrosis factor (TNF) antagonists have proved effective as treatment against rheumatoid arthritis (RA), but the unresolved issue of whether the use of anti-TNF therapy increases the already elevated risk of lymphoma in RA remains a concern.
Methods: Using the Swedish Biologics Register (ARTIS), the Swedish Cancer Register, pre-existing RA cohorts and cross-linkage with other national health and census registers, a national RA cohort (n = 67,743) was assembled and patients who started anti-TNF therapy between 1998 and July 2006 (n = 6604) were identified. A general population comparator (n = 471,024) was also assembled and the incidence of lymphomas from 1999 to 31 December 2006 was assessed and compared in these individuals.
Results: Among the 6604 anti-TNF-treated RA patients, 26 malignant lymphomas were observed during 26,981 person-years of follow-up, which corresponded to a relative risk (RR) of 1.35 (95% CI 0.82 to 2.11) versus anti-TNF-naive RA patients (336 lymphomas during 365,026 person-years) and 2.72 (95% CI 1.82 to 4.08) versus the general population comparator (1568 lymphomas during 3,355,849 person-years). RA patients starting anti-TNF therapy in 1998-2001 accounted for the entire increase in lymphoma risk versus the two comparators. By contrast, RR did not vary significantly by time since start of first treatment or with the accumulated duration of treatment, nor with the type of anti-TNF agent.
Conclusion: Overall and as used in routine care against RA, TNF antagonists are not associated with any major further increase in the already elevated lymphoma occurrence in RA. Changes in the selection of patients for treatment may influence the observed risk.
Similar articles
- Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
Geborek P, Bladström A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT. Geborek P, et al. Ann Rheum Dis. 2005 May;64(5):699-703. doi: 10.1136/ard.2004.030528. Epub 2005 Feb 4. Ann Rheum Dis. 2005. PMID: 15695534 Free PMC article. - Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundström C, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L, Feltelius N. Askling J, et al. Ann Rheum Dis. 2005 Oct;64(10):1414-20. doi: 10.1136/ard.2004.033241. Epub 2005 Apr 20. Ann Rheum Dis. 2005. PMID: 15843454 Free PMC article. - Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L. Askling J, et al. Arthritis Rheum. 2009 Nov;60(11):3180-9. doi: 10.1002/art.24941. Arthritis Rheum. 2009. PMID: 19877027 - The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
Leombruno JP, Einarson TR, Keystone EC. Leombruno JP, et al. Ann Rheum Dis. 2009 Jul;68(7):1136-45. doi: 10.1136/ard.2008.091025. Epub 2008 Aug 27. Ann Rheum Dis. 2009. PMID: 18753157 Review.
Cited by
- Remicade® (infliximab): 20 years of contributions to science and medicine.
Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Melsheimer R, et al. Biologics. 2019 Jul 30;13:139-178. doi: 10.2147/BTT.S207246. eCollection 2019. Biologics. 2019. PMID: 31440029 Free PMC article. Review. - Prevalence and Factors Associated with De-escalation of Anti-TNFs in Older Adults with Rheumatoid Arthritis: A Medicare Claims-Based Observational Study.
Lee J, Kumar N, Kabeto M, Galecki A, Chang CH, Singh N, Yung R, Makris UE, Bynum JPW. Lee J, et al. Drugs Aging. 2024 Jul;41(7):601-613. doi: 10.1007/s40266-024-01125-w. Epub 2024 Jun 20. Drugs Aging. 2024. PMID: 38900379 - The practical value of biologics registries in Africa and Middle East: challenges and opportunities.
Hajjaj-Hassouni N, Al-Badi M, Al-Heresh A, Al-Emadi S, El Bawendi A, El Garf A, El Hadidi K, Halabi H, Hammoudeh M, El Hassani S, Al Maaini M, Nahar I, Ladjouze Rezig A, Sellami S, Sweiri W, Alswailem R, Traub B, Uthman I, van Duuren E, Zakraoui L, El Zorkany B, Carmona L, Dougados M. Hajjaj-Hassouni N, et al. Clin Rheumatol. 2012 Mar;31(3):407-16. doi: 10.1007/s10067-011-1918-8. Epub 2012 Jan 7. Clin Rheumatol. 2012. PMID: 22228237 Review. - Anti-TNF Alpha and Risk of Lymphoma in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Imam AA. Imam AA. Medicina (Kaunas). 2024 Jul 17;60(7):1156. doi: 10.3390/medicina60071156. Medicina (Kaunas). 2024. PMID: 39064585 Free PMC article. Review. - Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Mercer LK, Galloway JB, Lunt M, Davies R, Low AL, Dixon WG, Watson KD; BSRBR Control Centre Consortium; Symmons DP, Hyrich KL. Mercer LK, et al. Ann Rheum Dis. 2017 Mar;76(3):497-503. doi: 10.1136/annrheumdis-2016-209389. Epub 2016 Aug 8. Ann Rheum Dis. 2017. PMID: 27502891 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical